SB
ANIK icon

Suntrust Banks’s Anika Therapeutics ANIK Stock Holding History

Suntrust Banks’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-23,142
Closed -$950K – 1412
2014
Q1 		$950K Buy
+23,142
New +$860K ﹤0.01% 983

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Suntrust Banks's ANIK Position: Q2 2014 in Review

Suntrust Banks sold out of Anika Therapeutics (ANIK) in Q2 2014, closing a stake of 23,142 shares — an estimated $950K sold.

Suntrust Banks first reported a position in ANIK in Q1 2014 and held it in 1 quarter. The position peaked at $950K in Q1 2014. 162 funds tracked by Wall St. Rank hold ANIK as of Q2 2014.

  • Suntrust Banks reported no remaining Anika Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Suntrust Banks sold 23,142 Anika Therapeutics shares in Q2 2014, an estimated $950K.
  • Suntrust Banks first reported a position in Anika Therapeutics in Q1 2014 and held it in 1 quarter.
  • Suntrust Banks's Anika Therapeutics position peaked at $950K in Q1 2014.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2014.

Based on Suntrust Banks's 13F filing for Q2 2014, filed 14 Aug 2014.